{
    "root": "7c509112-dd21-4383-9c46-59cd44d91d73",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SIMVASTATIN",
    "value": "20250127",
    "ingredients": [
        {
            "name": "SIMVASTATIN",
            "code": "AGG2FN16EV"
        },
        {
            "name": "ASCORBIC ACID",
            "code": "PQ6CK8PD0R"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        }
    ],
    "indications": "Simvastatin tablets USP are indicated:\n                  \n                     To reduce the risk of total      mortality by reducing risk of coronary heart disease death, non-fatal      myocardial infarction and stroke, and the need for coronary and      non-coronary revascularization procedures in adults with established      coronary heart disease, cerebrovascular disease, peripheral vascular      disease, and/or diabetes, who are at high risk of coronary heart disease events.\n                     As an adjunct to diet to reduce      low-density lipoprotein cholesterol (LDL-C):\n                           In adults with primary      hyperlipidemia.\n                           In adults and pediatric      patients aged 10 years and older with heterozygous familial      hypercholesterolemia (HeFH).\n                        \n                     \n                  \n                  \n                     As an adjunct to other      LDL-C-lowering therapies to reduce LDL-C in adults with homozygous      familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the      treatment of adults with:\n                           Primary dysbetalipoproteinemia.\n                           Hypertriglyceridemia.",
    "contraindications": "Important      Dosage and Administration Information : ( 1 ) Take simvastatin tablets USP orally once daily in the evening. Maximum recommended dosage is simvastatin tablets USP 40 mg once daily. An 80 mg daily dosage of      simvastatin tablets USP is restricted to patients who      have been taking simvastatin tablets USP 80 mg      daily chronically (e.g., for 12 months or more) without evidence of muscle      toxicity. For patients that require a high-intensity statin or are unable      to achieve their LDL-C goal receiving simvastatin      tablets USP 40 mg daily, prescribe alternative      LDL-C lowering treatment. Assess LDL-C when clinically appropriate, as early as 4 weeks      after initiating, and adjust the dosage if necessary. Adults : Recommended dosage is 20 mg      to 40 mg once daily. ( 2.2 ) Pediatric Patients Aged 10 Years and Older with HeFH : Recommended dosage is 10 mg to 40 mg once daily. ( 2.3 ) Patients with Severe Renal Impairment : Recommended starting dosage is simvastatin 5 mg once daily. ( 2.4 , 8.6 ) See full prescribing information for simvastatin tablets USP dosage      modifications due to drug interactions. ( 2.5 )",
    "warningsAndPrecautions": "Simvastatin Tablets USP, 5 mg are tan colored, round, biconvex, film-coated tablets, debossed with 'LL' on one side and 'C01' on the other side. They are supplied as follows:\n                  \n                     NDC 68180-482-06                Bottles of 30*\n                  \n                  \n                     NDC 68180-482-09                Bottles of 90*\n                  \n                  \n                     NDC 68180-482-03                Bottles of 1000*\n                  \n                  Simvastatin Tablets USP, 10 mg are peach colored, oval shaped, biconvex, film-coated tablets, debossed with 'LL' on one side and 'C02' on the other side. They are supplied as follows:\n                  \n                     NDC 68180-478-01                Bottles of 30\n                  \n                     NDC 68180-478-02                Bottles of 90\n                  \n                     NDC 68180-478-03                Bottles of 1000\n                  Simvastatin Tablets USP, 20 mg are tan colored, oval shaped, biconvex, film-coated tablets, debossed with 'LL' on one side and 'C03' on the other side. They are supplied as follows:\n                  \n                     NDC 68180-479-01                Bottles of 30\n                  \n                     NDC 68180-479-02                Bottles of 90\n                  \n                     NDC 68180-479-03                Bottles of 1000\n                  Simvastatin Tablets USP, 40 mg are brick red colored, round shaped, biconvex, film-coated tablets, debossed with 'LL' on one side and 'C04' on the other side. They are supplied as follows:\n                  \n                     NDC 68180-464-06                Bottles of 30\n                  \n                     NDC 68180-464-09                Bottles of 90\n                  \n                     NDC 68180-464-03                Bottles of 1000\n                  Simvastatin Tablets USP, 80 mg are brick red colored, capsule shaped, biconvex, film-coated tablets, debossed with 'LL' on one side and 'C05' on the other side. They are supplied as follows:\n                  \n                     NDC 68180-465-06                Bottles of 30\n                  \n                     NDC 68180-465-09                Bottles of 90\n                  \n                     NDC 68180-465-03                Bottles of 1000\n                  *The 5 mg strength of Simvastatin Tablets USP is no longer being marketed.\n                  \n                     Storage\n                  \n                  Store between 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].\n                  Preserve in tight container as defined in USP.",
    "adverseReactions": "Simvastatin is contraindicated in the following conditions:\n                  \n                     Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see DRUG INTERACTIONS (7.1)].\n                     \n                     Concomitant use of cyclosporine, danazol or gemfibrozil [see DRUG INTERACTIONS (7.1)]. \n                     \n                     Acute liver failure or decompensated cirrhosis [see WARNINGS AND PRECAUTIONS (5.3)]\n                     \n                     Hypersensitivity to simvastatin or any excipients in simvastatin tablets USP. Hypersensitivity reactions, including anaphylaxis, angioedema and Stevens-Johnson syndrome, have been reported [see ADVERSE REACTIONS (6.2)]"
}